HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons.
SARS-CoV
adaptaquin
hypoxia inducible factor
neuradapt
roxadustat
vadadustat
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
10
2020
accepted:
31
12
2020
entrez:
15
2
2021
pubmed:
16
2
2021
medline:
16
2
2021
Statut:
epublish
Résumé
The review analyzes the potential advantages and problems associated with using HIF prolyl hydroxylase inhibitors as a treatment for COVID-19. HIF prolyl hydroxylase inhibitors are known to boost endogenous erythropoietin (Epo) and activate erythropoiesis by stabilizing and activating the hypoxia inducible factor (HIF). Recombinant Epo treatment has anti-inflammatory and healing properties, and thus, very likely, will be beneficial for moderate to severe cases of COVID-19. However, HIF PHD inhibition may have a significantly broader effect, in addition to stimulating the endogenous Epo production. The analysis of HIF target genes reveals that some HIF-targets, such as furin, could play a negative role with respect to viral entry. On the other hand, HIF prolyl hydroxylase inhibitors counteract ferroptosis, the process recently implicated in vessel damage during the later stages of COVID-19. Therefore, HIF prolyl hydroxylase inhibitors may serve as a promising treatment of COVID-19 complications, but they are unlikely to aid in the prevention of the initial stages of infection.
Identifiants
pubmed: 33584306
doi: 10.3389/fphar.2020.621054
pii: 621054
pmc: PMC7878396
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
621054Informations de copyright
Copyright © 2021 Poloznikov, Nersisyan, Hushpulian, Kazakov, Tonevitsky, Kazakov, Vechorko, Nikulin, Makarova and Gazaryan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Respir Physiol Neurobiol. 2020 Jun;277:103443
pubmed: 32333993
Clin J Am Soc Nephrol. 2016 Jun 6;11(6):982-91
pubmed: 27094610
Eur J Med Chem. 2016 Sep 14;120:252-74
pubmed: 27191619
Am J Physiol Lung Cell Mol Physiol. 2009 Oct;297(4):L631-40
pubmed: 19592460
Cell. 2012 May 25;149(5):1060-72
pubmed: 22632970
FASEB J. 2003 Apr;17(6):761-3
pubmed: 12594177
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Annu Rev Med. 2017 Jan 14;68:387-399
pubmed: 27576010
Acta Physiol (Oxf). 2010 Apr;198(4):457-63
pubmed: 19922526
Pediatr Nephrol. 2019 Mar;34(3):365-378
pubmed: 29569190
Clin Exp Pharmacol Physiol. 2009 Sep;36(9):904-11
pubmed: 19298539
Intensive Care Med Exp. 2020 Sep 15;8:53
pubmed: 32953400
Oncol Rep. 2016 Feb;35(2):992-8
pubmed: 26718775
J Neurosci Res. 2009 May 15;87(7):1686-94
pubmed: 19156859
J Immunol. 2011 Jan 15;186(2):764-74
pubmed: 21169549
J Med Chem. 2018 Aug 23;61(16):6964-6982
pubmed: 29712435
J Endocr Soc. 2017 Apr 1;1(4):370-384
pubmed: 29082356
Int J Infect Dis. 2021 Feb;103:415-419
pubmed: 33249285
Antioxidants (Basel). 2020 Jul 24;9(8):
pubmed: 32722310
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4
pubmed: 7539918
Nat Rev Gastroenterol Hepatol. 2017 Oct;14(10):596-611
pubmed: 28853446
Sci Immunol. 2020 May 13;5(47):
pubmed: 32404436
J Appl Physiol (1985). 2000 Jun;88(6):2219-26
pubmed: 10846039
Free Radic Biol Med. 2019 Mar;133:130-143
pubmed: 30268886
J Cell Mol Med. 2012 Sep;16(9):2049-59
pubmed: 22128786
FEBS J. 2020 Sep;287(18):3888-3906
pubmed: 32446269
Bioorg Med Chem Lett. 2009 May 15;19(10):2852-5
pubmed: 19359167
J Am Soc Nephrol. 2016 Apr;27(4):1225-33
pubmed: 26494833
Pharmacol Res. 2011 Sep;64(3):268-73
pubmed: 21504793
Int J Infect Dis. 2020 Aug;97:303-305
pubmed: 32497811
Exp Cell Res. 2011 Dec 10;317(20):2789-99
pubmed: 21951999
J Biol Chem. 1995 Jan 20;270(3):1230-7
pubmed: 7836384
J Eur Acad Dermatol Venereol. 2020 Sep 25;:
pubmed: 32977363
Cell Metab. 2020 Sep 1;32(3):437-446.e5
pubmed: 32697943
Rev Panam Salud Publica. 2020 Jun 01;44:e72
pubmed: 32547616
J Eur Acad Dermatol Venereol. 2020 Sep 25;:
pubmed: 32977355
Clin Kidney J. 2020 Sep 02;13(4):494-499
pubmed: 32905208
Endocr Metab Immune Disord Drug Targets. 2020;20(6):807-811
pubmed: 32338224
J Mol Cell Cardiol. 2012 Dec;53(6):848-57
pubmed: 23085511
Clin Sci (Lond). 2014 Apr;126(7):507-16
pubmed: 24147777
Brain Res. 2016 Feb 1;1632:19-26
pubmed: 26707978
Am J Nephrol. 2017;45(5):380-388
pubmed: 28343225
J Pharmacol Exp Ther. 2017 Dec;363(3):336-347
pubmed: 28928122
Neural Regen Res. 2020 Aug;15(8):1539-1545
pubmed: 31997820
Biochem J. 1994 Jun 1;300 ( Pt 2):525-30
pubmed: 8002959
Mol Med. 2020 Jun 16;26(1):58
pubmed: 32546125
Nutrients. 2020 Aug 07;12(8):
pubmed: 32784601
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Front Aging Neurosci. 2018 Apr 27;10:121
pubmed: 29755339
Kidney Int. 2016 Nov;90(5):1115-1122
pubmed: 27650732
Biochimie. 2018 Apr;147:46-54
pubmed: 29289682
Science. 2001 Nov 9;294(5545):1337-40
pubmed: 11598268
Microorganisms. 2020 Jun 12;8(6):
pubmed: 32545679
Curr Clin Microbiol Rep. 2020 Apr 20;:1-7
pubmed: 32318324
Biochim Biophys Acta. 2015 Oct;1847(10):1254-66
pubmed: 26143176
Gastroenterology. 2003 Oct;125(4):1011-7
pubmed: 14517783
J Physiol. 2006 Jul 1;574(Pt 1):33-9
pubmed: 16709637
J Biol Chem. 2012 Sep 28;287(40):33594-606
pubmed: 22865883
Curr Top Med Chem. 2020;20(16):1423-1433
pubmed: 32416679
Eur J Pharmacol. 2019 Jan 15;843:113-120
pubmed: 30458168
J Inflamm (Lond). 2020 Oct 29;17:33
pubmed: 33139969
J Biol Chem. 2005 Feb 25;280(8):6561-9
pubmed: 15611046
Exp Neurol. 2016 Jun;280:13-23
pubmed: 26996132
Med Hypotheses. 2020 Oct;143:109857
pubmed: 32464493
Biochem Biophys Res Commun. 2018 Sep 5;503(2):1057-1062
pubmed: 29935187
J Neurochem. 2005 May;93(3):513-25
pubmed: 15836611
Drug Metab Lett. 2019;13(1):45-52
pubmed: 30488807
Front Immunol. 2020 Aug 07;11:1969
pubmed: 32849658
Neurobiol Dis. 2020 Mar;136:104725
pubmed: 31911115
Pharmacol Res. 2020 Jul;157:104859
pubmed: 32360480
Science. 2001 Apr 20;292(5516):468-72
pubmed: 11292861
Internist (Berl). 2019 Nov;60(11):1136-1145
pubmed: 31455974
Bioorg Med Chem Lett. 2006 Nov 1;16(21):5687-90
pubmed: 16908145
Chem Biol. 2010 Apr 23;17(4):380-91
pubmed: 20416509
Drug Discov Today. 2020 Aug;25(8):1528-1534
pubmed: 32562843
J Med Virol. 2020 Jul;92(7):726-730
pubmed: 32221983
J Biol Chem. 2001 Jun 29;276(26):24301-8
pubmed: 11301321
Kidney Int. 2020 May;97(5):934-950
pubmed: 32171449
Hemodial Int. 2017 Jun;21 Suppl 1:S110-S124
pubmed: 28449418
Biochem Biophys Res Commun. 2005 Dec 9;338(1):627-38
pubmed: 16153592
Blood. 2007 Nov 15;110(10):3610-7
pubmed: 17684156
Acta Pharmacol Sin. 2020 Dec;41(12):1539-1546
pubmed: 33110240